Literature DB >> 21476955

Opioids, sleep, and sleep-disordered breathing.

Moshe Zutler1, Jon-Erik C Holty.   

Abstract

Opioid medications are increasingly used to treat chronic pain. Opioid-associated respiratory depression, and their potential to cause nocturnal apneas, is increasingly recognized as a major contributor to nocturnal hypoxemia and sleep-disordered breathing. Given the widespread use of opioids, understanding their mechanism of action and their potential to cause adverse effects particularly during sleep is critical. This article reviews the salient features of the physiologic control of respiration and sleep, and the role opioids play in altering that regulation. Additionally, we summarize the evidence regarding the association between opioid use and sleep-disordered breathing and explore treatment modalities for opioid-associated nocturnal respiratory depression and apneas.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21476955     DOI: 10.2174/138161211796197070

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  16 in total

Review 1.  Adverse events associated with medium- and long-term use of opioids for chronic non-cancer pain: an overview of Cochrane Reviews.

Authors:  Charl Els; Tanya D Jackson; Diane Kunyk; Vernon G Lappi; Barend Sonnenberg; Reidar Hagtvedt; Sangita Sharma; Fariba Kolahdooz; Sebastian Straube
Journal:  Cochrane Database Syst Rev       Date:  2017-10-30

2.  Fentanyl effects on breath generation in C57BL/6J and A/J mouse strains.

Authors:  Linnea Fechtner; Mazen El Ali; Abdus Sattar; Michael Moore; Kingman P Strohl
Journal:  Respir Physiol Neurobiol       Date:  2015-04-30       Impact factor: 1.931

3.  Effects on breathing of agonists to μ-opioid or GABAA receptors dialyzed into the ventral respiratory column of awake and sleeping goats.

Authors:  Thomas M Langer; Suzanne E Neumueller; Emma Crumley; Nicholas J Burgraff; Sawan Talwar; Matthew R Hodges; Lawrence Pan; Hubert V Forster
Journal:  Respir Physiol Neurobiol       Date:  2017-01-27       Impact factor: 1.931

4.  Sleep Disturbances in Australian Vietnam Veterans With and Without Posttraumatic Stress Disorder.

Authors:  Timothy Baird; Sarah McLeay; Wendy Harvey; Rebecca Theal; Dayna Law; Robyn O'Sullivan
Journal:  J Clin Sleep Med       Date:  2018-05-15       Impact factor: 4.062

5.  Detailed Polysomnography in Australian Vietnam Veterans With and Without Posttraumatic Stress Disorder.

Authors:  Timothy Baird; Rebecca Theal; Sarah Gleeson; Sarah McLeay; Robyn O'Sullivan; Sarah McLeay; Wendy Harvey; Madeline Romaniuk; Darrell Crawford; David Colquhoun; Ross McD Young; Miriam Dwyer; John Gibson; Robyn O'Sullivan; Graham Cooksley; Christopher Strakosch; Rachel Thomson; Joanne Voisey; Bruce Lawford
Journal:  J Clin Sleep Med       Date:  2018-09-15       Impact factor: 4.062

Review 6.  [Long-term opioid therapy in chronic noncancer pain. A systematic review and meta-analysis of efficacy, tolerability and safety in open-label extension trials with study duration of at least 26 weeks].

Authors:  W Häuser; K Bernardy; C Maier
Journal:  Schmerz       Date:  2015-02       Impact factor: 1.107

Review 7.  Chronic hypoventilation syndromes and sleep-related hypoventilation.

Authors:  Sebastian Böing; Winfried J Randerath
Journal:  J Thorac Dis       Date:  2015-08       Impact factor: 2.895

8.  Evaluation of a noninvasive algorithm for differentiation of obstructive and central hypopneas.

Authors:  Winfried J Randerath; Marcel Treml; Christina Priegnitz; Sven Stieglitz; Lars Hagmeyer; Christian Morgenstern
Journal:  Sleep       Date:  2013-03-01       Impact factor: 5.849

Review 9.  Cannabinoids for neuropathic pain.

Authors:  Perry G Fine; Mark J Rosenfeld
Journal:  Curr Pain Headache Rep       Date:  2014-10

10.  Prescription of Long-Acting Opioids and Mortality in Patients With Chronic Noncancer Pain.

Authors:  Wayne A Ray; Cecilia P Chung; Katherine T Murray; Kathi Hall; C Michael Stein
Journal:  JAMA       Date:  2016-06-14       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.